Evidence map›Paper›PMID 36510335›Full record

ArticleEndocrine reviews2023

Bone Turnover Markers: Basic Biology to Clinical Applications.

Marian Schini, Tatiane Vilaca, Fatma Gossiel, Syazrah Salam, Richard Eastell

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094568 (Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.), which is not on this map. Cited by 216 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
216citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07094568 recruitingnot on this mapstarted 2025, after this paper: background citation

Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.

TypeobservationalSponsorNational and Kapodistrian University of AthensRan2025 to 2026Enrolled72ConditionsObesity (Disorder)
3 · Its place in the literature

Who cites it

216 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
    Pooled it
  11. Trial
  12. Trial
  13. Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

156 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marian SchiniDepartment of Oncology and Metabolism, University of Sheffield, Sheffield S10 2HQ, UK.ORCID 0000-0003-2204-2095
Tatiane VilacaDepartment of Oncology and Metabolism, University of Sheffield, Sheffield S10 2HQ, UK.
Fatma GossielDepartment of Oncology and Metabolism, University of Sheffield, Sheffield S10 2HQ, UK.ORCID 0000-0002-1433-2001
Syazrah SalamDepartment of Oncology and Metabolism, University of Sheffield, Sheffield S10 2HQ, UK.
Richard EastellDepartment of Oncology and Metabolism, University of Sheffield, Sheffield S10 2HQ, UK.ORCID 0000-0002-0323-3366

Funding

Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the last 20 years, much experience has been gained in measurement and interpretation of these markers, which include commonly used bone formation markers (bone alkaline phosphatase, osteocalcin, and procollagen I N-propeptide); and commonly used resorption markers (serum C-telopeptides of type I collagen, urinary N-telopeptides of type I collagen, and tartrate-resistant acid phosphatase type 5b). BTMs are usually measured by enzyme-linked immunosorbent assay or automated immunoassay. Sources contributing to BTM variability include uncontrollable factors (eg, age, gender, ethnicity) and controllable factors, particularly relating to collection conditions (eg, fasting/feeding state, and timing relative to circadian rhythms, menstrual cycling, and exercise). Pregnancy, season, drugs, and recent fracture(s) can also affect BTMs. BTMs correlate with other methods of assessing bone turnover, such as bone biopsies and radiotracer kinetics, and can usefully contribute to diagnosis and management of several diseases such as osteoporosis, osteomalacia, Paget's disease, fibrous dysplasia, hypophosphatasia, primary hyperparathyroidism, and chronic kidney disease-mineral bone disorder.

Indexed as

Bone ResorptionCollagen Type IAcid PhosphataseAlkaline PhosphataseBiologyBone RemodelingHumansAcid PhosphataseAlkaline PhosphataseCollagen Type Ibiochemical markers of bone turnoverbone alkaline phosphataseC-telopeptides of type I collagenosteocalcintartrate-resistant acid phosphatase 5burinary N-telopeptides of type I collagen

Identifiers

PMID36510335
PMCPMC10166271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.